Adalimumab Treatment in Biologically Naïve Crohn’s Disease : Relationship with Ectopic MUC5AC Expression and Endoscopic Improvement
Joint Authors
Kamiya, Takeshi
Tanida, Satoshi
Katano, Takahito
Nishiwaki, Hirotaka
Kubota, Eiji
Ozeki, Keiji
Joh, Takashi
Mori, Yoshinori
Ebi, Masahide
Mizoshita, Tsutomu
Tsukamoto, Hironobu
Kataoka, Hiromi
Source
Gastroenterology Research and Practice
Issue
Vol. 2014, Issue 2014 (31 Dec. 2014), pp.1-8, 8 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2014-04-16
Country of Publication
Egypt
No. of Pages
8
Main Subjects
Abstract EN
Background.
Adalimumab (ADA) is effective for patients with Crohn’s disease (CD).
However, there have been few reports on ADA therapy with respect to its relationship with pathologic findings and drug efficacy in biologically naïve CD cases.
Methods.
Fifteen patients with active biologically naïve CD were treated with ADA.
We examined them clinically and pathologically with ectopic MUC5AC expression in the lesions before and after 12 and 52 weeks of ADA therapy, retrospectively.
Results.
Both mean CD activity index scores and serum C-reactive protein values were significantly lower after ADA therapy (P<0.001).
In the MUC5AC negative group, all cases exhibited clinical remission (CR) and endoscopic improvement at 52 weeks.
In MUC5AC positive groups, loss of MUC5AC expression was detected in cases having CR and endoscopic improvement at 52 weeks, while remnant ectopic MUC5AC expression was observed in those exhibiting no endoscopic improvement and flare up after 52 weeks.
Conclusions.
ADA leads to CR and endoscopic improvement in biologically naïve CD cases.
In addition, ectopic MUC5AC expression may be a predictive marker of flare up and endoscopic improvement in the intestines of CD patients.
American Psychological Association (APA)
Mizoshita, Tsutomu& Tanida, Satoshi& Tsukamoto, Hironobu& Ozeki, Keiji& Katano, Takahito& Nishiwaki, Hirotaka…[et al.]. 2014. Adalimumab Treatment in Biologically Naïve Crohn’s Disease : Relationship with Ectopic MUC5AC Expression and Endoscopic Improvement. Gastroenterology Research and Practice،Vol. 2014, no. 2014, pp.1-8.
https://search.emarefa.net/detail/BIM-490622
Modern Language Association (MLA)
Mizoshita, Tsutomu…[et al.]. Adalimumab Treatment in Biologically Naïve Crohn’s Disease : Relationship with Ectopic MUC5AC Expression and Endoscopic Improvement. Gastroenterology Research and Practice No. 2014 (2014), pp.1-8.
https://search.emarefa.net/detail/BIM-490622
American Medical Association (AMA)
Mizoshita, Tsutomu& Tanida, Satoshi& Tsukamoto, Hironobu& Ozeki, Keiji& Katano, Takahito& Nishiwaki, Hirotaka…[et al.]. Adalimumab Treatment in Biologically Naïve Crohn’s Disease : Relationship with Ectopic MUC5AC Expression and Endoscopic Improvement. Gastroenterology Research and Practice. 2014. Vol. 2014, no. 2014, pp.1-8.
https://search.emarefa.net/detail/BIM-490622
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-490622